News Gist .News

Articles | Politics | Finance | Stocks | Crypto | AI | Technology | Science | Gaming | PC Hardware | Laptops | Smartphones | Archive

ClearPoint Neuro Full Year 2024 Earnings: Misses Expectations

ClearPoint Neuro (NASDAQ:CLPT) Full Year 2024 Results Key Financial Results Revenue: US$31.4m (up 31% from FY 2023). Net loss: US$18.9m (loss narrowed by 14% from FY 2023). US$0.70 loss per share (improved from US$0.90 loss in FY 2023).

See Also

Clariant Full Year 2024 Earnings: EPS Misses Expectations Δ1.80

Clariant's full-year 2024 earnings missed expectations, with revenue down 5.1% from FY 2023 and net income up 45%. The company's profit margin increased to 5.9%, driven by lower expenses, but the earnings per share (EPS) fell short of analyst estimates. Despite this, revenue is forecast to grow at a slower pace than the Chemicals industry in Switzerland over the next three years.

Avepoint Full Year 2024 Earnings: Eps Misses Expectations Δ1.80

AvePoint's full-year 2024 earnings failed to meet expectations, with revenue surging 22% from the previous year but net losses widening by 34%. The company's shares have taken a hit, falling 16% from a week ago. AvePoint's performance is part of the broader American software industry, which has seen growth forecasts of 12% per annum.

Calumet Full Year 2024 Earnings: EPS Beats Expectations Δ1.79

Calumet's full-year 2024 earnings surprise analysts, with revenue flat on FY 2023 and a net loss of $222.0m, down from a profit of $47.1m in FY 2023. The company's shares have declined 4.0% from a week ago, despite beating analyst estimates for EPS by 5.1%. Looking ahead, revenue is forecast to grow 6.6% p.a. on average during the next 3 years.

Brainchip Holdings Posts Slightly Improved Full Year 2024 Earnings Amid Reduced Losses Δ1.78

BrainChip Holdings reported a net loss of US$24.4m, narrowing by 15% from the previous year's loss of US$28.6m. The company also achieved an improved loss per share of US$0.012, compared to US$0.016 in FY 2023. BrainChip Holdings shares are down 31% from a week ago.

Fulgent Genetics Full Year 2024 Earnings: Eps Beats Expectations Δ1.77

Fulgent Genetics' full-year 2024 earnings report shows revenue down 2.0% from FY 2023, but the company's loss narrowed by 75%, with a net loss of US$42.7m and a loss per share of US$1.41. The company's earnings per share (EPS) surpassed analyst estimates by 17%. Fulgent Genetics forecasts revenue growth of 11% p.a. on average during the next 2 years, outpacing the Healthcare industry in the US at 7.1%.

Cronos Group Full Year 2024 Earnings: Revenue Beats Expectations, Eps Lags Δ1.77

Cronos Group's full year 2024 earnings report shows revenue growth of 35% compared to the previous year, with a net income of US$41.1m, but missing analyst estimates by 2.0%. The company's profit margin has increased to 35%, and earnings per share (EPS) have declined to US$0.11, down from a loss of US$0.18 in the previous year. Revenue growth is forecasted to be 11% p.a. over the next three years.

Ctac Reports Full Year 2024 Earnings Δ1.77

Ctac has reported its full-year 2024 financial results, revealing a revenue of €124.6 million, which reflects a 2.1% decline from the previous year. Despite the drop in revenue, net income surged by 245% to €3.91 million, resulting in an improved profit margin of 3.1% due to reduced expenses. Looking forward, the company anticipates a revenue growth of 4.4% annually over the next two years, slightly below the broader IT industry forecast in Europe.

Par Technology Full Year 2024 Earnings: Eps Beats Expectations, Revenues Lag Δ1.77

PAR Technology's full year 2024 earnings beat analyst expectations, but revenue missed estimates by 16%, with a net loss widening by 29% from the previous year. The company's shares have increased by 10% over the past week, driven by its strong EPS performance. However, the revenue decline and widening losses raise concerns about the company's financial health.

ModivCare Full Year 2024 Earnings: EPS Misses Expectations Δ1.76

ModivCare's full year 2024 earnings missed analyst estimates by a significant margin, with the company reporting a net loss of US$201.3m, narrower than the previous year's loss of US$214.9m. Revenue grew 1.3% to US$2.79b, driven primarily by its NEMT segment, but the impact on earnings was substantial due to high cost of sales. The company's shares have declined 17% from a week ago.

Chart Industries Full Year 2024 Earnings: Misses Expectations Δ1.75

Chart Industries' full-year 2024 earnings exceeded analyst expectations, with revenue growing by 24% to US$4.16 billion and net income increasing by US$174.2 million to US$194.8 million. The company's profit margin expanded to 4.7%, driven by higher revenue, while earnings per share (EPS) rose to US$4.62, surpassing analyst estimates by 26%. Despite the positive results, revenue missed analyst expectations by 1.5%.

Corbion Beats Expectations Despite Revenue Decline Δ1.75

Corbion, a Netherlands-based chemicals company, reported full-year 2024 earnings that beat analyst estimates, despite a decline in revenue of 11% compared to the previous year. The company's net income decreased by 37%, but its profit margin remained relatively stable at 3.6%. Looking ahead, Corbion forecasts growth of 5.1% per annum for the next three years.

BCE Full Year 2024 Earnings: EPS Misses Expectations Δ1.75

BCE's full-year 2024 earnings per share (EPS) missed analyst estimates by a significant margin, with the actual figure coming in at CA$0.18 compared to expectations of CA$2.28. The company's net income plummeted 92% from the previous year, resulting in a profit margin of just 0.7%. Revenue was in line with analyst estimates but still down 1.1% from the prior year.

Caq Holdings Full Year 2024 Earnings: Share Price Remains Stable Despite Profitable Loss Δ1.75

CAQ Holdings' Full Year 2024 Results Key Financial Results Net loss: AU$3.83m (loss widened by 22% from FY 2023). AU$0.005 loss per share (further deteriorated from AU$0.004 loss in FY 2023). The company's profitability may be impacted by the significant increase in operating expenses.

Osteopore's Full Year 2024 Earnings: A Slight Improvement Δ1.75

Osteopore reported a narrower net loss of AU$3.24m, a 33% reduction from the previous year, with revenue increasing by 27% to AU$2.81m. The company's shares are down 3.6% from a week ago, highlighting the risks associated with investing in Osteopore. Despite this, the improved financial performance suggests that the company is taking steps towards reducing its losses.

South Plains Financial Full Year 2024 Earnings: Beats Expectations Δ1.75

South Plains Financial's full-year 2024 earnings exceeded analyst expectations, with revenue decreasing by 9.5% and net income down 21%. The company's profit margin declined to 26%, driven by lower revenue, while its EPS grew by 11% above estimates. Revenue is forecast to grow 6.9% on average over the next two years.

Holcim Full Year 2024 Earnings Miss Expectations Δ1.75

Holcim's full-year 2024 results missed analyst expectations, with revenue declining 2.2% to CHF26.4 billion and net income falling 3.8%. The company's profit margin remained steady at 11%, but earnings per share (EPS) missed estimates by 7.1%. Looking ahead, Holcim forecasts average annual revenue growth of 4.7% over the next three years.

Amrep Third Quarter 2025 Earnings Outperform Expectations Δ1.74

AMREP reported a third-quarter revenue of US$7.52m, down 41% from the same period last year, and net income of US$717.0k, up by US$625.0k from 3Q 2024. The increase in margin was driven by lower expenses, with profit margins rising to 9.5%, up from 0.7% in 3Q 2024. Earnings per share (EPS) grew to US$0.14, beating analyst expectations.

Eco Wave Power Global's Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line Δ1.74

Eco Wave Power Global has reported full year 2024 earnings with revenues beating expectations, while the net loss of US$2.08m was narrower than anticipated, representing a 22% decrease from FY 2023. The company's shares have still taken a hit, falling 3.7% from last week. Despite this, revenue growth is forecast to outpace that of the broader renewable energy industry over the next two years.

Schroders Full Year 2024 Earnings: Beats Expectations Δ1.74

Schroders' full year 2024 earnings have exceeded analyst estimates by 1.0%, with revenue rising to UK£3.02 billion (up 1.0% from FY 2023). The company's net income also surged to UK£417.0 million (up 7.4% from FY 2023), driven by strong profit margins of 14%. These results demonstrate Schroders' ability to navigate challenging market conditions and deliver solid performance.

Sunrun Full Year 2024 Earnings: Eps Misses Expectations Δ1.74

Sunrun's full-year 2024 earnings missed analyst expectations significantly, with revenue down 9.8% from the previous year and a net loss of $2.85 billion, widening by 77% from 2023. The company's shares have fallen 14% from last week, reflecting investor concerns over its performance. Despite forecasted revenue growth of 10% per annum for the next three years, Sunrun faces challenges in the competitive American electrical industry.

Cardiff Oncology Beats Expectations in Full Year 2024 Earnings Δ1.74

Cardiff Oncology's full year 2024 earnings have exceeded analyst estimates, with a net loss of US$45.5m and a loss per share of US$0.95, wider than the previous year's loss of US$0.93. The company's revenue surpassed expectations by 12%, beating forecasts for growth in the biotechs industry in the US. Looking ahead, Cardiff Oncology's revenue is forecast to grow at an average rate of 52% per annum over the next three years.

WisdomTree Full Year 2024 Earnings: EPS Misses Expectations Δ1.74

WisdomTree's full-year 2024 earnings missed analyst estimates by 17%, with revenue up 23% from the previous year and net income down 48%. The company's profit margin declined to 12%, a significant drop from 27% in FY 2023. Despite this, WisdomTree's shares have been impacted, falling 1.7% from a week ago.

Mooreast Holdings Full Year 2024 Earnings: s$0.009 Loss per Share (vs s$0.007 Loss in Fy 2023) Δ1.74

Mooreast Holdings's full-year 2024 earnings report reveals a significant deterioration in the company's financial performance, with revenue decreasing by 13% year-over-year and net losses widening by 25%. The company's shares have surged 18% from last week, but this move may be driven more by speculation than by a strong underlying recovery. The loss per share has further increased to S$0.009, highlighting the need for substantial financial support.

Fubotv Projects Subscriber Fall in Q1 After Q4 Topline Growth, Stock Tumbles Δ1.74

FuboTV Inc (NYSE:FUBO) reported earnings for the fourth quarter of 2024, with revenue growing 8.1% year over year to $443.277 million, marginally missing analyst expectations. Adjusted EPS loss of 2 cents beat analyst estimates, while the company's adjusted EBITDA margin loss stood at (2.0)% versus (12.2)% Y/Y. The company's paid subscribers grew 6.2% Y/Y to 1.64 million in North America.

The Future of Pearson's Growth Depends on Its Balance Sheet Δ1.74

Pearson's full-year 2024 earnings report shows a mixed bag, with revenue down 3.3% and EPS beating estimates by 14%. The company's profit margin increased to 12%, driven by lower expenses, but this growth is not translating to the bottom line as expected. Despite missing analyst revenue estimates, Pearson's share price remains unchanged.